
UB670
IndicationsDry age-related macular degeneration
ClinicalCN - Preclinical
TherapeuticsOphthalmology
ModalitiesNucleic Acid Therapeutics
Exclusive Summary
- First-in-class CPP (cell-penetrating peptide) siRNA for age-related macular degeneration (AMD), targeting a potential market of $1.6 billion.
我们能如何帮助您?
获取最新活动与法规动态洞察
直接发送到您的邮箱
在此获取行业洞察与 Unibest 动态
联系我们 →